Dissemin is shutting down on January 1st, 2025

Published in

Baishideng Publishing Group, World Journal of Cardiology, 6(2), p. 131, 2010

DOI: 10.4330/wjc.v2.i6.131

Links

Tools

Export citation

Search in Google Scholar

Alternatives to clopidogrel for acute coronary syndromes: Prasugrel or ticagrelor?

Journal article published in 2010 by Giuseppe Biondi Zoccai, Marzia Lotrionte, Fiorenzo Gaita, Giuseppe Biondi-Zoccai ORCID
This paper is made freely available by the publisher.
This paper is made freely available by the publisher.

Full text: Download

Red circle
Preprint: archiving forbidden
Red circle
Postprint: archiving forbidden
Green circle
Published version: archiving allowed
Upload
Policy details
Data provided by SHERPA/RoMEO

Abstract

Clopidogrel is a mainstay in the treatment of patients with acute coronary syndromes or those receiving endovascular prostheses. However, its efficacy has been challenged in the recent past by studies suggesting variable individual responsiveness and by new, more potent competitors, such as prasugrel and ticagrelor. But what is the actual body of evidence in support of clopidogrel? Is there any dark side of the moon? What is the role of prasugrel, which has already been approved in Europe and in the United States? And what will be the future role of ticagrelor, when approved for routine clinical practice? We hereby concisely summarize the scope of this clinical choice, providing arguments in favor and against each of the three antiplatelet agents: clopidogrel, prasugrel, and ticagrelor.